The Investment Whisperer
  • Business
  • Politics
  • Investing
  • World
  • Business
  • Politics
  • Investing
  • World

The Investment Whisperer

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

by admin December 20, 2024
December 20, 2024
RAD 202 receives approval to start Phase 1 therapeutic trial

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0
FacebookTwitterGoogle +Pinterest
previous post
Westgold Shares Scoping Study for Expansion of Fortnum Gold Operation
next post
Forum Comments on Share Price

Related Posts

The Mar-a-Lago Accord: What it is and What...

March 13, 2025

Copper and Consequences: US Tariffs Stir Uncertainty in...

April 15, 2025

5 Best-performing Canadian Uranium Stocks of 2024

October 18, 2024

Successful completion of Lac Carheil drilling program

April 10, 2025

Challenger Gold Doubles Ecuador Resource to 9.1¹ Million...

April 9, 2025

Board Approves Development of Boorara

August 3, 2024

Sona Nanotech Secures Grant Funding to Support Intellectual...

April 9, 2024

Top 5 Small-cap Pharma Stocks in 2025

April 9, 2025

Canadian North Resources Inc. Provides an Update on...

April 4, 2024

Amgen, Merck and Pfizer Release Latest Quarterly Earnings,...

February 5, 2025

    Stay updated with the latest news, exclusive offers, and special promotions. Sign up now and be the first to know! As a member, you'll receive curated content, insider tips, and invitations to exclusive events. Don't miss out on being part of something special.


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Categories

    • Business (1,402)
    • Investing (3,381)
    • Politics (4,562)
    • World (4,498)
    • About us
    • Contact us
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: TheInvestmentWhisperer.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

    Copyright © 2024 TheInvestmentWhisperer.com | All Rights Reserved